id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0880-0030,FDA,FDA-2012-D-0880,Draft Guidance for Industry - Assessing User Fees Under the Generic Drug User Fee Amendments of 2017,Other,Guidance,2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2024-11-12T23:11:37Z,,1,0,09000064841152bd
FDA-2012-D-0880-0029,FDA,FDA-2012-D-0880,"Assessing User Fees Under the Generic Drug User Fee Amendments of
2017; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,2020-01-01T04:59:59Z,2019-12-21T02:01:25Z,2019-23875,0,0,0900006484113ec1